Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are a growing biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. Alnylam is leading the translation of RNAi into a new class of medicines with a core focus on developing therapeutics directed toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options available for patients and their caregivers.